Sanofi (NASDAQ:SNY) Position Boosted by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC increased its holdings in Sanofi (NASDAQ:SNY) by 10.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,179 shares of the company’s stock after purchasing an additional 6,893 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Sanofi were worth $3,433,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Synergy Asset Management LLC acquired a new position in Sanofi in the fourth quarter worth approximately $25,000. McClarren Financial Advisors Inc. boosted its stake in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares in the last quarter. Lee Danner & Bass Inc. bought a new stake in shares of Sanofi during the 4th quarter worth $31,000. Sunbelt Securities Inc. grew its holdings in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new stake in shares of Sanofi during the fourth quarter worth $44,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Price Performance

Shares of SNY opened at $55.82 on Monday. The business’s 50-day moving average is $55.13 and its 200-day moving average is $52.76. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market capitalization of $141.66 billion, a price-to-earnings ratio of 22.42, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.